Lykos, FDA Discuss Phase 3 MDMA Trial Plans

October 20, 2024

Study: Psilocybin Boosts Optimism

October 10, 2024

SEC Charges Phony Psilocybin Company

October 10, 2024

Study: Millions Could Benefit From Psilocybin-Assisted Therapy

September 19, 2024

Study: Low-Dose Ketamine Could Reduce Fentanyl Withdrawal Symptoms

September 19, 2024

Lykos Therapeutics Slashes Workforce, Reshuffles Leadership After FDA Rejection

August 22, 2024